Few cases of chalazia secondary to bortezomib are reported in literature. However, it is not a recognized ocular adverse effect. We hereby report a case of recurrent chalazia secondary to bortezomib. A 40-year-old male with light chain myeloma on ten weeks of chemotherapy with bortezomib was treated for left eye inflamed chalazion with bilateral meibominitis. Severe chalazia persisted despite treatment, which necessitated cessation of chemotherapy. The patient’s condition improved on oral doxycycline and chemotherapy was recommenced but his chalazia recurred, necessitating incision and curretage. His chalazia responded to oral azithromycin without further cessation of chemotherapy. Bortezomib’s association with chalazia has been characterized as a possible adverse drug reaction according to the World Health organization classification, and its recognization as an established adverse reaction to will allow earlier identification and appropriate co-management of the patient.
Recurrent Chalazia Secondary to Bortezomib
Author
Abstrak
Kes chalazia yang disebabkan oleh bortezomib pernah dilaporkan namun ia bukanlah dikenalpasti sebagai satu kesan sampingan kepada bortezomib. Kami dengan ini melaporkan kes chalazion yang berulang disebabkan rawatan bortezomib. Seorang pesakit lelaki berusia 40 tahun yang menghidap myeloma rantaian ringan telah mengalami chalazia di mata kiri dan meibominitis di keduadua belah mata selepas sepuluh minggu menerima rawatan kemoterapi dengan bortezomib. Walaupun dirawat, chalazia pesakit tidak pulih hingga menyebabkan rawatan bortezomib dihentikan. Setelah ubat doxycycline diberi, chalazia pesakit semakin pulih dan rawatan kemoterapi disambung, namun chalazia pesakit berulang kembali dan memerlukan incision & curretage. Rawatan dengan azithromycin telah mengecutkan chalazia pesakit tanpa perlu menghentikan kemoterapi. Hubungan antara bortezomib dan chalazia telah dicirikan sebagai reaksi ubat yang berkemungkinan menurut klasifikasi World Health Organization, dan pengiktirafannya sebagai reaksi ubat akan membolehkan pengenalan awal dan pengurusan bersama pesakit dengan pakar onkologi.
Kata kunci
Abstract
Keywords
|
|
